UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Adults with mild autonomous cortisol secretion who undergo an adrenalectomy have a significantly reduced risk for vertebral ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

Discover top income-generating picks inspired by Berkshire Hathaway. Learn how to achieve financial independence with yields ...

The recent buyout offer by Sycamore Partners is likely to be approved and is the best option for shareholders. Find out why ...

The initial public offering (IPO) of Accretion Pharmaceuticals opened for subscription today, May 14, 2025. The SME public ...

Kirkpatrick noted that the company continues to work on the development of its lead product, PF614, an extended-release oxycodone to treat severe pain, as well as its combination product, PF614-MPAR, ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands ...

In terms of saving Americans money - on our taxes, our health insurance and our out-of-pocket expenses - this policy idea potentially dwarfs anything and everything the Trump administration has ...